^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dacarbazine

    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    9d
    Plexin A2 Knockdown Enhances Apoptosis in Chemotherapy Treated Melanoma Cells. (PubMed, Oncol Res)
    This study elucidates alterations in adhesion molecule expression in melanoma cells acquiring resistance to dacarbazine (DTIC) and entering the G0 state...These findings suggest that PLXNA2 down-regulation in DTIC-treated cancer cells promotes their apoptosis. Therefore, targeting focal adhesion molecules during chemotherapy can increase the sensitivity of tumor cells to anticancer treatment.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)
    |
    dacarbazine
    10d
    Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (clinicaltrials.gov)
    P2, N=340, Active, not recruiting, Merck Sharp & Dohme LLC | N=243 --> 340
    Enrollment change
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • dacarbazine • bleomycin • vinblastine
    10d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=108 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    10d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=108, Recruiting, Immatics US, Inc.
    New P3 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    12d
    Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • dacarbazine • vinblastine
    16d
    Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment (clinicaltrials.gov)
    P2, N=23, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Oct 2029 | Trial primary completion date: Nov 2027 --> Oct 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • gemcitabine • Adcetris (brentuximab vedotin) • dacarbazine
    17d
    A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma (ChiCTR2600118298)
    P2, N=92, Beijing Cancer Hospital (Peking University Cancer Hospital); Beijing Cancer Hospital (Peking University Cancer Hospital)
    New P2 trial
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation • NRAS mutation • BRAF V600 • BRAF positive
    |
    cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • LM103
    18d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    24d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=96, Recruiting, Immatics US, Inc.
    New P3 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    25d
    Adriamycin, Vinblastine and Dacarbazine With Immunotherapy Achieves Complete Metabolic Response in a Patient With Classical Hodgkin Lymphoma and Dyskeratosis Congenita. (PubMed, J Hematol)
    To mitigate pulmonary and myelotoxicity risks, he received a modified regimen of brentuximab vedotin (BV) combined with adriamycin, vinblastine, and dacarbazine (BV-AVD), with full omission of bleomycin. It underscores the critical need for individualized therapy in patients with DC and supports careful consideration of radiation omission to reduce secondary malignancy risk. These findings provide a potential therapeutic framework for managing Hodgkin lymphoma in patients with DC.
    Journal • IO biomarker
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine
    26d
    S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
    1m
    Chemotherapy Supports Cancer Cell Dissemination in a Melanoma Preclinical Model. (PubMed, Asian Pac J Cancer Prev)
    Taken together, dacarbazine and the miR-204-5p mimic favor the dissemination of B16 melanoma cells in the lungs, which may support further metastatic development. Although miR-204-5p has been described as a tumor-suppressive microRNA in melanoma, the application of a synthetic mimic to overexpress it in distant organs promoted tumor cell dissemination.
    Preclinical • Journal
    |
    PMEL (Premelanosome Protein) • MIR204 (MicroRNA 204)
    |
    dacarbazine